Drug Hunter
Home > AZD4573
short engagement, selective CDK9 kinase inh.
IV treatment in Ph. I for RR-heme cancers
shortened t1/2 from prior preclin. candidate
J. Med. Chem., Dec. 11, 2020
AstraZeneca, Cambridge, UK / Boston, MA
AstraZeneca selective CDK9 kinase inhibitor
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
December 2020
Molecules of the Month
02
February
01
January
03
March
04
April
05
May
06
June
07
July
08
August
09
September
10
October
11
November
12
December
MOTY Nominees
Molecule of the Year